SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
29 févr. 2024 08h35 HE
|
SciSparc Ltd
The SCI- 210 treatment is now available at clinical site for autism spectrum disorder clinical trial in pediatric patients, in accordance with enrollment initiation TEL AVIV, Israel, Feb. 29,...
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
27 févr. 2024 07h58 HE
|
SciSparc Ltd
TEL AVIV, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
20 févr. 2024 07h14 HE
|
SciSparc Ltd
TEL AVIV, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
29 janv. 2024 07h18 HE
|
SciSparc Ltd
The clinical trial for SCI-210 will be conducted in Israel, after which the company aims to move forward with the commercialization process of SCI-210 first in the Israeli market TEL AVIV,...
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
24 janv. 2024 07h42 HE
|
SciSparc Ltd
TEL AVIV, Israel, Jan. 24, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of...
SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million
19 janv. 2024 09h28 HE
|
SciSparc Ltd
TEL AVIV, Israel, Jan. 19, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments
04 janv. 2024 07h18 HE
|
SciSparc Ltd
The collaboration included six different provisional patent applications filed by Clearmind with the United States Patent and Trademark Office in February 2023 to protect the novel combinations of...
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
13 déc. 2023 08h18 HE
|
SciSparc Ltd
MitoCareX Bio met its second milestone as part of its joint venture agreement with the Company TEL AVIV, Israel, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or...
SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel
07 déc. 2023 09h05 HE
|
SciSparc Ltd
TEL AVIV, Israel, Dec. 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial
01 déc. 2023 08h14 HE
|
SciSparc Ltd
The collaboration between SciSparc and Clearmind continues to yield positive results in its obesity and metabolic disorder program TEL AVIV, Israel, Dec. 01, 2023 (GLOBE NEWSWIRE) -- SciSparc...